GlassScriptPhysician profile
William Reid Cluff
NPI 1922536085
$7,909.22
in general payments reported to CMS, 2019-2025
15 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 94% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $32.93 · 2021: $537 · 2022: $375 · 2023: $649 · 2024: $3,779 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,277 · Food and Beverage: $2,149 · Consulting Fee: $1,850 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,277.31 |
| Food and Beverage | $2,149.31 |
| Consulting Fee | $1,850.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,951.20 | 2019-2025 | Air Optix, Wavelight Refractive Suite, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $2,306.17 | 2024-2025 | Infuse |
| Coopervision INC. | $937.34 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Paragon Crt |
| Johnson & Johnson Vision Care, INC. | $787.00 | 2020-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $252.14 | 2019-2021 | |
| Biotissue Holdings INC. | $211.48 | 2024 | |
| Sight Sciences, INC. | $144.62 | 2023 | Tearcare System |
| Tarsus Pharmaceuticals, INC. | $133.48 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $45.33 | 2023-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $40.97 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Janssen Pharmaceuticals, INC | $29.46 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.89 | 2023 | Purified Cortrophin Gel |
| Abbvie INC. | $21.40 | 2023 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $12.37 | 2021 | |
| Maculogix, INC. | $10.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cluff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.